## Vana Sypsa

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6907879/publications.pdf

Version: 2024-02-01

110 papers	7,394 citations	94433 37 h-index	83 g-index
117	117	117	9661 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. Journal of Hepatology, 2022, 76, 302-310.	3.7	48
2	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2022, 20, 1343-1353.e16.	4.4	9
3	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2022, 76, 311-318.	3.7	48
4	Age-dependent effects on infectivity and susceptibility to SARS-CoV-2 infection: results from nationwide contact tracing data in Greece. Infectious Diseases, 2022, 54, 186-195.	2.8	11
5	Dating the Origin and Estimating the Transmission Rates of the Major HIV-1 Clusters in Greece: Evidence about the Earliest Subtype A1 Epidemic in Europe. Viruses, 2022, 14, 101.	3.3	2
6	Head-to-Head Comparison of Response Rates to the Two mRNA SARS-CοV-2 Vaccines in a Large Cohort of Solid Organ Transplant (SOT) Recipients. Vaccines, 2022, 10, 190.	4.4	12
7	Ongoing HIV transmission following a large outbreak among people who inject drugs in Athens, Greece (2014–20). Addiction, 2022, 117, 1670-1682.	3.3	4
8	A Network Approach to Determine Optimization of PrEP Uptake in Athens, Greece. AIDS and Behavior, 2022, , 1.	2.7	0
9	Is Mandatory Vaccination in Population over 60 Adequate to Control the COVID-19 Pandemic in E.U.?. Vaccines, 2022, 10, 329.	4.4	2
10	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 285.	4.4	13
11	Trends in COVID-19 Vaccination Intent, Determinants and Reasons for Vaccine Hesitancy: Results from Repeated Cross-Sectional Surveys in the Adult General Population of Greece during November 2020–June 2021. Vaccines, 2022, 10, 470.	4.4	18
12	Identifying Country-Level Risk Factors for the Spread of COVID-19 in Europe Using Machine Learning. Viruses, 2022, 14, 625.	3.3	1
13	Modeling the impact of interventions during an outbreak of HIV infection among people who inject drugs in 2012–2013 in Athens, Greece Drug and Alcohol Dependence, 2022, 234, 109396.	3.2	2
14	Evaluating the effects of second-dose vaccine-delay policies in European countries: A simulation study based on data from Greece. PLoS ONE, 2022, 17, e0263977.	2.5	5
15	A Proposed Etiology for an Aberrant Response to Enteric Adenovirus Infection in Previously SARS-CoV-2-Infected Children With Acute Hepatitis. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 352-353.	1.3	7
16	Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B― Journal of Hepatology, 2021, 74, 246-247.	3.7	1
17	Food insecurity among people who inject drugs in Athens, Greece: a study in the context of ARISTOTLE programme. Public Health Nutrition, 2021, 24, 813-818.	2.2	1
18	Epidemiology: Modeling of Natural History. , 2021, , 175-188.		O

#	Article	IF	CITATIONS
19	Sexual Mixing and HIV Transmission Potential Among Greek Men Who have Sex with Men: Results from SOPHOCLES. AIDS and Behavior, 2021, 25, 1935-1945.	2.7	4
20	Effects of Social Distancing Measures during the First Epidemic Wave of Severe Acute Respiratory Syndrome Infection, Greece. Emerging Infectious Diseases, 2021, 27, 452-462.	4.3	31
21	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health, The, 2021, 6, e309-e323.	10.0	99
22	Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020. MSphere, 2021, 6, e0018021.	2.9	8
23	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Reports, 2021, 3, 100290.	4.9	5
24	Validation of molecular clock inferred HIV infection ages: Evidence for accurate estimation of infection dates. Infection, Genetics and Evolution, 2021, 91, 104799.	2.3	4
25	Living in Roma Settlements in Greece: Self-Perceived Health Status, Chronic Diseases and Associated Social Determinants of Health. International Journal of Environmental Research and Public Health, 2021, 18, 8403.	2.6	2
26	Pre-exposure Prophylaxis Persistence Among Greek Sexual Minority Men: Results from PrEP for Greece (P4G) Study. AIDS and Behavior, 2021, , 1.	2.7	1
27	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines, 2021, 9, 1017.	4.4	10
28	Outbreaks of SARS-CoV-2 in naturally infected mink farms: Impact, transmission dynamics, genetic patterns, and environmental contamination. PLoS Pathogens, 2021, 17, e1009883.	4.7	26
29	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. Eurosurveillance, 2021, 26, .	7.0	4
30	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 2020, 73, 1368-1378.	3.7	158
31	The Emotion of Disgust among Medical and Psychology Students. Diseases (Basel, Switzerland), 2020, 8, 43.	2.5	0
32	HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV,the, 2020, 7, e434-e442.	4.7	62
33	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2020, 73, 1037-1045.	3.7	69
34	Containing Carbapenemase-producing Klebsiella pneumoniae in an endemic setting. Antimicrobial Resistance and Infection Control, 2020, 9, 102.	4.1	10
35	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2020, 72, 1088-1096.	3.7	75
36	High-risk behaviors and their association with awareness of HIV status among participants of a large-scale prevention intervention in Athens, Greece. BMC Public Health, 2020, 20, 105.	2.9	8

3

#	Article	IF	CITATIONS
37	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. PLoS ONE, 2020, 15, e0243025.	2.5	45
38	Design and Development of a Viral Hepatitis and HIV Infection Screening Program (Hprolipsis) for the General, Greek Roma, and Migrant Populations of Greece: Protocol for Three Cross-Sectional Health Examination Surveys. JMIR Research Protocols, 2020, 9, e13578.	1.0	5
39	Presenting a conceptual framework for an HIV prevention and care continuum and assessing the feasibility of empirical measurement in Estonia: A case study. PLoS ONE, 2020, 15, e0240224.	2.5	2
40	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19., 2020, 15, e0243025.		0
41	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. , 2020, 15, e0243025.		O
42	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19., 2020, 15, e0243025.		0
43	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. , 2020, 15, e0243025.		0
44	A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study. Journal of Viral Hepatitis, 2019, 26, 1311-1317.	2.0	7
45	Why do HIV outbreaks re-emerge among people who inject drugs?. Lancet HIV,the, 2019, 6, e274-e275.	4.7	7
46	Aiming towards hepatitis C virus elimination in Greece. Annals of Gastroenterology, 2019, 32, 321-329.	0.6	7
47	THU-427-A community-based fast-track seek-test-treat program to enhance diagnosis and linkage to care for hepatitis C infection among people who inject drugs in Athens, Greece (ARISTOTLE HCV-HIV) Tj ETQq1	l 0.784 <b>3:17</b> rgBT	/ <b>©</b> verlock
48	Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World Journal of Gastroenterology, 2019, 25, 1327-1340.	3.3	13
49	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. Journal of Virus Eradication, 2019, 5, 60-66.	0.5	49
50	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. Journal of Virus Eradication, 2019, 5, 60-66.	0.5	34
51	Molecular Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)–Infected Individuals in a Network-Based Intervention (Transmission Reduction Intervention Project): Phylogenetics Identify HIV-1–Infected Individuals With Social Links. Journal of Infectious Diseases, 2018, 218, 707-715.	4.0	18
52	Molecular investigation of HIV-1 cross-group transmissions during an outbreak among people who inject drugs (2011–2014) in Athens, Greece. Infection, Genetics and Evolution, 2018, 62, 11-16.	2.3	11
53	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of Hepatology, 2018, 68, 1129-1136.	3.7	88
54	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241

#	Article	IF	CITATIONS
55	HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era. PLoS ONE, 2018, 13, e0202109.	2.5	24
56	Knowledge, Normative Beliefs and Attitudes Related to Recent HIV Infection among People who Inject Drugs in Athens, Greece. Current HIV Research, 2018, 15, 386-395.	0.5	0
57	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
58	Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?. Addiction, 2017, 112, 1290-1299.	3.3	42
59	Rapid decline of HIV incidence among people who inject drugs during a fast-track combination prevention programme following an HIV outbreak in Athens. Journal of Infectious Diseases, 2017, 215, 1496-1505.	4.0	48
60	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 2017, 66, 1444-1453.	7.3	239
61	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 325-336.	8.1	208
62	Molecular Tracing of the Geographical Origin of Human Immunodeficiency Virus Type 1 Infection and Patterns of Epidemic Spread Among Migrants Who Inject Drugs in Athens. Clinical Infectious Diseases, 2017, 65, 2078-2084.	5.8	19
63	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduction Journal, 2017, 14, 19.	3.2	33
64	Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 466-472.	2.8	10
65	A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP). Scientific Reports, 2016, 6, 38100.	3.3	60
66	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. Journal of Hepatology, 2016, 64, 800-806.	3.7	358
67	A case–control study of <i><scp>MC</scp>1R</i> variants in Greek patients with basal cell carcinoma: increased risk independently of pigmentary characteristics. Experimental Dermatology, 2015, 24, 476-478.	2.9	5
68	The interferon receptorâ€1 promoter polymorphisms affect the outcome of Caucasians with <scp>HB</scp> eAgâ€negative chronic <scp>HBV</scp> infection. Liver International, 2015, 35, 2506-2513.	3.9	12
69	Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction, 2015, 110, 1453-1467.	3.3	62
70	Network Characteristics of People Who Inject Drugs Within a New HIV Epidemic Following Austerity in Athens, Greece. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 499-508.	2.1	24
71	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. Journal of Hepatology, 2015, 62, 363-370.	3.7	138
72	Big Events in Greece and HIV Infection Among People Who Inject Drugs. Substance Use and Misuse, 2015, 50, 825-838.	1.4	47

#	Article	IF	CITATIONS
73	Homelessness and Other Risk Factors for HIV Infection in the Current Outbreak Among Injection Drug Users in Athens, Greece. American Journal of Public Health, 2015, 105, 196-204.	2.7	50
74	Enhanced HIV-1 surveillance using molecular epidemiology to study and monitor HIV-1 outbreaks among intravenous drug users (IDUs) in Athens and Bucharest. Infection, Genetics and Evolution, 2015, 35, 109-121.	2.3	36
75	National Income Inequality and Declining GDP Growth Rates Are Associated with Increases in HIV Diagnoses among People Who Inject Drugs in Europe: A Panel Data Analysis. PLoS ONE, 2015, 10, e0122367.	2.5	37
76	Histological features of chronic hepatitis C in haemodialysis patients. Liver International, 2014, 34, e56-61.	3.9	3
77	Socially-Integrated Transdisciplinary HIV Prevention. AIDS and Behavior, 2014, 18, 1821-1834.	2.7	39
78	Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems. Antimicrobial Agents and Chemotherapy, 2014, 58, 2322-2328.	3.2	520
79	Time of acquisition of <scp>HCV</scp> infection in renal transplant recipients: a major prognostic factor for disease progression. Clinical Transplantation, 2013, 27, 72-79.	1.6	6
80	Integrating Phylodynamics and Epidemiology to Estimate Transmission Diversity in Viral Epidemics. PLoS Computational Biology, 2013, 9, e1002876.	3.2	57
81	Economic Recession and Emergence of an HIV-1 Outbreak among Drug Injectors in Athens Metropolitan Area: A Longitudinal Study. PLoS ONE, 2013, 8, e78941.	2.5	97
82	Transmission Dynamics of Carbapenemase-Producing Klebsiella Pneumoniae and Anticipated Impact of Infection Control Strategies in a Surgical Unit. PLoS ONE, 2012, 7, e41068.	2.5	52
83	The Impact of the Heptavalent Pneumococcal Conjugate Vaccine on the Epidemiology of Acute Otitis Media Complicated by Otorrhea. Pediatric Infectious Disease Journal, 2011, 30, 551-555.	2.0	71
84	Epidemiologic risk factors of basal cell carcinoma development and age at onset in a Southern European population from Greece. Experimental Dermatology, 2011, 20, 622-626.	2.9	38
85	Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece. Virology Journal, 2011, 8, 10.	3.4	8
86	Estimating the Disease Burden of 2009 Pandemic Influenza A(H1N1) from Surveillance and Household Surveys in Greece. PLoS ONE, 2011, 6, e20593.	2.5	12
87	Hepatic progenitor cells in chronic hepatitis C: a phenomenon of older age and advanced liver disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 457-466.	2.8	25
88	Development of a new ultra sensitive real-time PCR assay (ultra sensitive RTQ-PCR) for the quantification of HBV-DNA. Virology Journal, 2010, 7, 57.	3 <b>.</b> 4	23
89	Impact of Hepatitis B Virus Infection on the Progression of AIDS and Mortality in HIVâ€Infected Individuals: A Cohort Study and Metaâ€Analysis. Clinical Infectious Diseases, 2009, 48, 1763-1771.	<b>5.</b> 8	193
90	Assessing the impact of biomedical research in academic institutions of disparate sizes. BMC Medical Research Methodology, 2009, 9, 33.	3.1	31

#	Article	IF	CITATIONS
91	Prevalence of different HPV types and estimation of prognostic risk factors based on the linear array HPV genotyping test. Journal of Medical Virology, 2009, 81, 2059-2065.	5.0	18
92	Sun exposure behavior and protection practices in a Mediterranean population: a questionnaireâ€based study. Photodermatology Photoimmunology and Photomedicine, 2009, 25, 132-137.	1.5	21
93	A study of a single variant allele (rs1426654) of the pigmentationâ€related gene SLC24A5 in Greek subjects. Experimental Dermatology, 2009, 18, 175-177.	2.9	10
94	Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation. Reproductive Biology and Endocrinology, 2009, 7, 110.	3.3	31
95	Risk associations of melanoma in a Southern European population: results of a case/control study. Cancer Causes and Control, 2008, 19, 671-679.	1.8	36
96	Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials. Statistics in Medicine, 2008, 27, 6505-6521.	1.6	7
97	The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized Study. Clinical Infectious Diseases, 2007, 45, 715-722.	5.8	238
98	Increasing Prevalence of HIV‹ Subtype A in Greece: Estimating Epidemic History and Origin. Journal of Infectious Diseases, 2007, 196, 1167-1176.	4.0	68
99	Human herpesvirus 8 (HHV-8) infection in healthy urban employees from Greece: Seroprevalence and associated factors. Journal of Medical Virology, 2007, 79, 591-596.	5.0	19
100	Seasonal pattern of the diagnosis of cutaneous melanoma: a hospitalâ€based study in a Mediterranean country. International Journal of Dermatology, 2007, 46, 1136-1140.	1.0	13
101	Melanocortin Receptor-1 Gene Polymorphisms and the Risk of Cutaneous Melanoma in a Low-Risk Southern European Population. Journal of Investigative Dermatology, 2006, 126, 1842-1849.	0.7	85
102	Human Herpesvirus 8 Infection in Hemodialysis Patients. American Journal of Kidney Diseases, 2006, 47, 167-170.	1.9	12
103	The Course of Hepatitis C Virus Infection in Pretransplantation Anti–Hepatitis C Virus–Negative Renal Transplant Recipients: A Retrospective Follow-Up Study. American Journal of Kidney Diseases, 2006, 47, 309-316.	1.9	42
104	Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assaysâ€"LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. Journal of Virological Methods, 2006, 131, 168-174.	2.1	36
105	Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients 1.  American Journal of Kidney Diseases, 2005, 45, 334-343.	1.9	63
106	Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. Journal of Virological Methods, 2004, 121, 93-99.	2.1	9
107	In vivo characteristics of human immunodeficiency virus type $1$ intersubtype recombination: determination of hot spots and correlation with sequence similarity. Journal of General Virology, 2003, 84, 2715-2722.	2.9	63
108	IFN-α2b Monotherapy in Patients with Chronic Hepatitis C and Persistently Normal or Near Normal Aminotransferase Activity: A Randomized, Controlled Study. Journal of Interferon and Cytokine Research, 2002, 22, 365-369.	1.2	9

#	Article	IF	CITATIONS
109	Low-Dose IFN-αMonotherapy in Treatment-Naive Individuals with HIV-1 Infection: Evidence of Potent Suppression of Viral Replication. Journal of Interferon and Cytokine Research, 2001, 21, 861-869.	1.2	41
110	Significance of IgM anti-HCVcore level in chronic hepatitis C. Journal of Hepatology, 1997, 27, 36-41.	3.7	17